Investigational drug · Phase 3
ZSP1273
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Influenza A, Influenza a.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
14
Any phase or sponsor naming "ZSP1273"
First trial start
2025
Nov 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ZSP1273", any sponsor or status.
Conditions studied
As listed on its trial records.
- Influenza A
- Influenza a
Approved drugs for the same conditions: Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "ZSP1273" as an intervention, largest first.
- A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza APivotal-lookingCompleted
Guangdong Raynovent Biotech Co., LtdIndustry
NCT04683406 · 750 participants · Start Dec 28, 2020 · Primary completion Apr 1, 2023
Drug: ZSP1273 600 mg; Placebo to Oseltamivir and 2 more · For: Influenza A
Sites: Bengbu, China; Xuancheng, China; Beijing, China · 76 sites in all
- Study of ZSP1273 in Patients With Acute Uncomplicated Influenza APivotal-lookingCompleted
Guangdong Raynovent Biotech Co., LtdIndustry
NCT04024137 · 172 participants · Start Dec 7, 2019 · Primary completion May 18, 2020
Drug: ZSP1273 200 mg; Placebo and 5 more · For: Influenza A
Sites: Hefei, China; Beijing, China; Xiamen, China · 26 sites in all
- Efficacy and Safety of ZSP1273 in Adolecent 12-17 Years Old With Influenza APivotal-lookingCompleted
Guangdong Raynovent Biotech Co., LtdIndustry
NCT07229820 · 157 participants · Start Nov 8, 2025 · Primary completion Dec 22, 2025
Drug: ZSP1273; Placebo · For: Influenza A
Sites: Shanghai, China
- Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza APivotal-lookingCompleted
Guangdong Raynovent Biotech Co., LtdIndustry
NCT07229807 · 120 participants · Start Nov 22, 2025 · Primary completion Jan 17, 2026
Drug: ZSP1273; Oseltamivir · For: Influenza a
Sites: Beijing, China
- The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.Pivotal-lookingCompleted
Guangdong Zhongsheng Pharmaceutical Co., Ltd.Industry
NCT03679143 · 103 participants · Start Sep 20, 2018 · Primary completion Mar 19, 2019
Drug: ZSP1273 100 mg; Placebo 100 mg and 18 more · For: Influenza
Sites: Changchun, China
- Pharmacokinetics,Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza ACompleted
Guangdong Raynovent Biotech Co., LtdIndustry
NCT06656026 · 72 participants · Start Nov 30, 2024 · Primary completion Jun 30, 2025
Drug: ZSP1273 granules · For: Influenza a
Sites: Guangzhou, China
Guangdong Raynovent Biotech Co., LtdIndustry
NCT05954624 · 49 participants · Start Jul 10, 2023 · Primary completion Nov 20, 2023
Drug: Digoxin; Rosuvastatin and 3 more · For: Drug Drug Interaction
Sites: Guangzhou, China
Guangdong Raynovent Biotech Co., LtdIndustry
NCT05108051 · 36 participants · Start Nov 19, 2020 · Primary completion Mar 17, 2021
Drug: ZSP1273; Oseltamivir · For: Drug-drug Interaction
Sites: Guangzhou, China
- Bioavailability Study in Healthy Participants, 200mg Tablets ZSP1273 Versus 200mg Granules ZSP1273Completed
Guangdong Raynovent Biotech Co., LtdIndustry
NCT06164431 · 32 participants · Start Nov 23, 2023 · Primary completion Dec 15, 2023
Drug: ZSP1273 tablet; zsp1273 granules · For: Bioequivalence
Sites: Guangzhou, China
Guangdong Raynovent Biotech Co., LtdIndustry
NCT06157450 · 32 participants · Start Oct 11, 2023 · Primary completion Nov 1, 2023
Drug: ZSP1273 · For: Elder
Sites: Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacokinetics, Safety, and Exploratory Efficacy of Onradivir in Children with Acute Uncomplicated Influenza: A Multicenter, Dose-Ranging, Phase 2 Study.
Qin Q, Ma C, Yang Y, et al. · Infect Dis Ther 2026
- Bioavailability of a novel anti-influenza agent, onradivir granules, in healthy Chinese adults: a first-in-human study.
Yi X, Liu Y, Wang X, et al. · Front Pharmacol 2026
- Population pharmacokinetic analysis of onradivir to support dosing recommendations in elderly adults with influenza.
Zheng XJ, Lv JX, Huang YH, et al. · Drug Metab Dispos 2026
- Pharmacokinetic insights of onradivir in influenza treatment to inform pediatric dosing selection in clinical trial.
Li H, Wang K, Sun Z, et al. · Drug Metab Dispos 2025
- Efficacy and safety of onradivir in adults with acute uncomplicated influenza A infection in China: a multicentre, double-blind, randomised, placebo-controlled and oseltamivir-controlled, phase 3 trial.
Yang Z, Zhan Y, Li Z, et al. · Lancet Respir Med 2025
- A phase I, single-center, randomized, open-label, three-period crossover study to evaluate the drug-drug interaction between ZSP1273 and oseltamivir in healthy Chinese subjects.
Pang Y, Li H, Chen X, et al. · Antimicrob Agents Chemother 2025
Also in development for Influenza A
- AZD4117Phase 21 trial
AstraZeneca · Influenza A
- AZD5315Phase 21 trial
AstraZeneca · Influenza A
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.